Daratumumab is a CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis. Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab.
- Mechanism
- Curator reviewed · 14 references
CD38 is a glycoprotein present on the surface of hematopoietic cells and is responsible for a number of cell signalling functions. Daratumumab is an immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that targets CD38. Cancers like multiple myeloma overexpress CD38, allowing daratumumab to have higher affinity for these cells. This binding allows daratumumab to induce apoptosis, antibody dependent cellular phagocytosis, and antibody and complement-dependent cytotoxicity. Antibody dependent cellular phagocytosis is mediated by the FC region of the antibody inducing phagocytes such as macrophages, antibody dependent cellular cytotoxicity is mediated by the FC region of the antibody inducing effector cells such as natural killer cells, and complement dependent cytotoxicity is mediated by the FC region of the antibody binding to and inducing complement protein activity.
- Primary indication
- Daratumumab is indicated as an intravenous injection, alone or in combination with other medications, for the treatment of multiple myeloma.Curator reviewed · 27 structured indications
- Formula / weight
- C6466H9996N1724O2010S42 · 145391.67 Da
- First approval
- Canada, 2016 · United States, 2015 · European Union, 2016
- Also known as
- Daratumumab-fihj
- Code names
- HLX15 · HuMax-CD 38 · JNJ-54767414
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Daratumumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account